Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.2% | -24.3% | -5.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.3% | 92.3% | 90.5% | 90.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | $0 |
| % Margin | -20.5% | -7.2% | 2.5% | 15.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -9.5% | 1.3% | 2.5% | 12.3% |
| EPS | -0.32 | 0.044 | 0.11 | 0.6 |
| % Growth | -832.3% | -60.3% | -81.7% | – |
| EPS Diluted | -0.32 | 0.044 | 0.11 | 0.58 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -16.4% | -5.7% | 3.6% | 16.8% |